Thronicke, A.; Grabowski, P.; Roos, J.; Wüstefeld, H.; Grah, C.; Johnson, S.; Schad, F.
Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). Int. J. Mol. Sci. 2025, 26, 3669.
https://doi.org/10.3390/ijms26083669
AMA Style
Thronicke A, Grabowski P, Roos J, Wüstefeld H, Grah C, Johnson S, Schad F.
Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). International Journal of Molecular Sciences. 2025; 26(8):3669.
https://doi.org/10.3390/ijms26083669
Chicago/Turabian Style
Thronicke, Anja, Patricia Grabowski, Juliane Roos, Hannah Wüstefeld, Christian Grah, Sophia Johnson, and Friedemann Schad.
2025. "Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW)" International Journal of Molecular Sciences 26, no. 8: 3669.
https://doi.org/10.3390/ijms26083669
APA Style
Thronicke, A., Grabowski, P., Roos, J., Wüstefeld, H., Grah, C., Johnson, S., & Schad, F.
(2025). Combined Immune Checkpoint Blockade and Helixor® Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). International Journal of Molecular Sciences, 26(8), 3669.
https://doi.org/10.3390/ijms26083669
